Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | IGF2R | P11717 | 4/20 | 0.30 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510032 | 0.78 | FBP1 (0.42) | FBP1AMDHD2CA1CA2CA4 | |
| SCHEMBL13951833 | 0.77 | FBP1 (0.37) | FBP1AMDHD2LPAR3LPAR1LPAR2 | |
| SCHEMBL6027002 | 0.77 | FBP1 (0.37) | FBP1 | |
| SCHEMBL3429348 | 0.73 | FBP1 (0.43) | FBP1CA1CA2S1PR1 | |
| SCHEMBL14527263 | 0.73 | CA1 (0.39) | CA1CA2CA4SCN9AEPHX1 | |
| SCHEMBL15385103 | 0.72 | FBP1 (0.44) | FBP1AMDHD2IGF2R | |
| SCHEMBL17481933 | 0.72 | FBP1 (0.44) | FBP1AMDHD2IGF2R | |
| SCHEMBL15381315 | 0.72 | FBP1 (0.44) | FBP1AMDHD2IGF2R | |
| SCHEMBL6026930 | 0.71 | SRC (0.45) | FBP1CA1CA2S1PR1 | |
| SCHEMBL16470991 | 0.71 | EPHX1 (0.36) | CA1CA2CA4SCN9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | FBP1 3682/4885AMDHD2 2497/4885CA1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.